Zacks Research Upgrades Lisata Therapeutics (NASDAQ:LSTA) to “Hold”

Lisata Therapeutics (NASDAQ:LSTA) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other research analysts also recently issued reports on the stock. downgraded shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. HC Wainwright downgraded shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $15.00.

Lisata Therapeutics Price Performance

NASDAQ:LSTA opened at $3.12 on Monday. The company has a fifty day moving average of $4.19 and a 200 day moving average of $3.37. Lisata Therapeutics has a 52 week low of $1.81 and a 52 week high of $5.07. The firm has a market capitalization of $28.42 million, a P/E ratio of -1.68 and a beta of 0.81.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Lisata Therapeutics will post -1.09 EPS for the current year.

Institutional Trading of Lisata Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Cerity Partners LLC purchased a new stake in shares of Lisata Therapeutics in the 2nd quarter worth about $32,000. CIBC Bancorp USA Inc. purchased a new stake in Lisata Therapeutics during the 3rd quarter valued at about $37,000. SOL Capital Management CO purchased a new stake in Lisata Therapeutics during the 1st quarter valued at about $61,000. Ground Swell Capital LLC purchased a new stake in Lisata Therapeutics during the 3rd quarter valued at about $62,000. Finally, Renaissance Technologies LLC grew its position in Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares during the last quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.